Filing Flows › Quantum-Si (QSI) › Guidance & outlook
Quantum-Si (QSI) guidance and outlook
Quantum-Si (QSI) lowered its guidance on Nov 5, 2026: Revenue $1.0M for FY2026; Operating expenses $87.0M for FY2026. Quantum-Si's 10-Q filed Nov 5, 2026 makes 19 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.0M | reaffirmed |
| Operating expenses | FY2026 | $87.0M | lowered |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- Unless the context otherwise requires, references to “we”, “us”, “our”, the “Company” or “Quantum-Si” are intended to mean the business and operations of Quantum-Si Incorporated and its consolidated subsidiaries.
- Our platform aims to address many of the key challenges and bottlenecks with legacy proteomic solutions, such as mass spectrometry (“MS”), which include high instrument costs both in terms of acquisition and ownership, and complexity with data analysis, which together limit broad adoption.
- We intend to continue to execute on this roadmap through a combination of internal development programs and external partnerships to bring to market the most comprehensive proteomics platform in our industry.
- We believe this new platform will provide much deeper
- As a result of the anticipated launch of Proteus, we expect some customers may delay purchasing decisions for existing products, which is expected to adversely impact revenue until Proteus becomes commercially available.
- Our restructuring activities are expected to be completed by the end of the fourth quarter of 2026 and we do not expect to incur material additional charges associated with these activities.
- We expect revenue in 2026 to continue to be impacted as customers may delay purchases ahead of Proteus becoming commercially available.
- We expect gross profit margin to be variable for the foreseeable future as we work through our continued commercialization efforts.
- We expect operating cash usage to continue to be impacted by operating results and working capital requirements.
- The net cash inflow reflected the ongoing management of our investment portfolio to optimize liquidity and align investment maturities with anticipated cash requirements, while preserving capital, minimizing exposure to market and credit risk, and supporting our ability to fund ongoing research and development initiatives and operating needs.
- We also expect our net invested capital balance to vary in future quarters as we fund our operating needs primarily through our investment portfolio.
- Going forward, we anticipate debt or equity offerings will be the primary source of funds to support our operating needs and capital expenditures until we reach scale of our commercial operations.
Quantum-Si's latest quarter
Quantum-Si, Q3 2026: revenue $212K (-62% year over year), net loss $22.3M, operating cash flow −$20.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did Quantum-Si raise or lower its guidance?
Quantum-Si (QSI) lowered its guidance on Nov 5, 2026: Revenue $1.0M for FY2026; Operating expenses $87.0M for FY2026.
What does Quantum-Si expect?
Unless the context otherwise requires, references to “we”, “us”, “our”, the “Company” or “Quantum-Si” are intended to mean the business and operations of Quantum-Si Incorporated and its consolidated subsidiaries. Our platform aims to address many of the key challenges and bottlenecks with legacy proteomic solutions, such as mass spectrometry (“MS”), which include high instrument costs both in terms of acquisition and ownership, and complexity with data analysis, which together limit broad adoption. We intend to continue to execute on this roadmap through a combination of internal development p
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.